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478ABSTRACT
Introduction. There is a lack of information regarding outcomes after liver transplant in
Latin America.
Objectives. This study sought to describe outcomes after liver transplant in adult patients
from Argentina.
Methods. We performed an ambispective cohort study of adult patients transplanted
between June 2010 and October 2012 in 6 centers from Argentina. Only patients who
survived after the first 48 hours postransplantation were included. Pretransplantation and
posttransplantation data were collected.
Results. A total of 200 patients were included in the study. Median age at time of
transplant was 50 (interquartile range [IQR] 26 to 54) years. In total, 173 (86%) patients
had cirrhosis, and the most frequent etiology in these patients was hepatitis C (32%). A
total of 35 (17%) patients were transplanted with hepatocellular carcinoma. In patients
with cirrhosis, the median Model for End-Stage Liver Disease (MELD) score at time of
liver transplant was 25 (IQR 19 to 30). Median time on the waiting list for elective
patients was 101 (IQR 27 to 295) days, and 3 (IQR 2 to 4) days for urgent patients.
Almost 40% of the patients were readmitted during the first 6 months after liver
transplant. Acute rejection occurred in 27% of the patients. Biliary and vascular
complications were reported in 39 (19%) and 19 (9%) patients, respectively. Renal
failure, diabetes, and dyslipidemia were present in 40 (26%), 87 (57%), and 77 (50%) at
2 years, respectively.
Conclusions. We believe the information contained in this article might be of value for
reviewing current practices and developing local policies.This study has received funds from Novartis in the setting of a
Third Party Trial.
*Address correspondence to Leila Haddad, Unidad de Tras-
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E-mail: Leila.haddad@hospitalitaliano.org.arLIVER transplant (LT) is a well-established therapeuticpractice in Argentina for patients with end-stage liver
disease. In Argentina, the first LT was performed in 1988,
and during past decades the annual number of LTs has
increased steadily, placing Argentina at the top of Latin
American LT rates [1]. This was possible due to the ad-
vances in surgical techniques, peritransplant intensive care,
and immunosuppressive regimens, which resulted in signif-
icant improvements in short-term survival.8
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LIVER TRANSPLANTATION IN ARGENTINA 479Although there is continual worldwide improvement in
patient survival, LT patients may experience serious com-
plications that not only contribute to significant morbidity
and mortality, but also represent an extremely high cost to
the health care system. A clear example of these are post-
LT infections, which are estimated to occur in more than
50% of the LT recipients, being one of the most frequent
complications during the early postoperative period [2,3]
and remaining the most common indication of hospital
readmission [3]. New-onset diabetes mellitus (NODM) after
LT is another well-known complication; it occurs in 2.5% to
25% [4] of LT recipients and in 40% to 60% of hepatitis C
viruseinfected LT recipients [5]. Chronic renal failure after
LT, mainly related to calcineurin inhibitors (CNI) toxicity
[6e8], continues to be a major complication, with an inci-
dence that ranges from 20% to 80%. In Argentina, studies
in patients on the waiting list and post-LT survival have
been published [9e11], although very limited data exist for
the post-LT period. Understanding post-LT complications
might be useful to develop strategies to predict and prevent
them, improving the quality of care and potentially reducing
overall costs. The aim of this study was to describe the
characteristics and outcomes of patients after LT in
Argentina.PATIENTS AND METHODS
We performed an ambispective multicenter cohort study of patients
who underwent LT from June 2010 to October 2012 in the 6 LT
centers from Argentina that performed the largest numbers of LT
when the study took place.
Argentina has a single national waiting list. The Instituto Nacio-
nal Central Único Coordinador de Ablación e Implante (INCUCAI)
is the national institute for organ allocation, and organ procurement
is exclusively run by the state, with no private procurement agencies.
Since Argentina adopted the Model for End-Stage Liver Disease
(MELD) system in 2005 as allocation policy, all patients were
grouped into 2 categories: emergency or elective. Emergency status
is considered for patients with acute liver failure and for patients
with primary graft failure or those with hepatic artery thrombosis
during the first postoperative week. Elective patients are stratified
according to the MELD score. A specific regulation includes 3
situations for MELD upgrading, which includes familial amyloidotic
polyneuropathy (16 points), hepatopulmonary syndrome (20
points), and stage II hepatocellular carcinoma (HCC) (22 points);
these regulations contemplate 1 additional point in MELD scores
every 3 months on the waiting list. By 2010 there were more than 20
authorized LT centers in Argentina, which has a population of
40,117,096 [12]. The centers involved in the study were the Hospital
Italiano de Buenos Aires, Hospital Universitario Fundación Fava-
loro, Sanatorio Allende de Cordoba, Hospital Universitario
Austral, Hospital Alemán and Hospital General de Agudos Dr.
Cosme Argerich.
Patients included in this study were older than 18 years and were
transplanted using a cadaveric donor. Exclusion criteria included
prior LT, combined transplant, and death during the first 48 hours
after LT. Patients were followed up from the day of LT until death,
retransplantation, or the end of the 2-year follow-up period.
Each center provided detailed information for the patients
included in the study. Data collection was performed using anelectronic form. The information collected included: demographics
(age/sex); date of enrollment on the waiting list; primary diagnosis
of liver disease at listing; Child-Pugh and MELD scores at inclusion
on the waitlist and at the day of transplantation; history of diabetes
before LT; donor characteristics; immunosuppression received;
laboratory determinations at months 1, 3, 6, 12 and 24 after LT;
medical and surgical complications; all-cause hospital readmissions;
and graft and patient survival. All data records were checked for
missing values and inconsistencies; queries were sent to all
participating institutions, and corrections were made at the data-
coordinating center, namely Hospital Italiano in Buenos Aires.
The estimated glomerular filtration rate (GFR) was calculated at
each time point with the Modified Diet in Renal Disease (MDRD)
GFR [13]. The definition of pre-LT diabetes included a history of
diabetes or use of insulin or oral hypoglycemic medications. The
definition of new-onset diabetes after transplantation (NODAT)
was based on International Consensus Guidelines on NODAT
2003, which recommended that the diagnosis of NODAT should be
based on the American Diabetes Association (ADA) criteria for
type 2 diabetes [14,15]. Dyslipidemia was defined using the National
Cholesterol Education Program (NCEP) Adult Treatment Panel
(ATP) III criteria [16]. Renal failure was defined as the presence of
a GFR of <50 mL/min/1.73 m2 using the MDRD equation. Liver
allograft rejection was diagnosed by biopsy according to Banff
criteria [17]. Patient management and immunosuppression regi-
mens were determined in each center. The study was conducted
according to the principles of the Declaration of Helsinki and the
Guidelines for Good Clinical Practices ICH E6. The study protocol
was approved by the ethics committees of the participating
hospitals.
STATISTICAL ANALYSIS
Discrete variables are presented as absolute and relative
frequencies (percentages). Continuous variables are shown
as median and interquartile ranges (IQR: 25th percentile
and 75th percentile). To estimate the cumulative incidence
of death, we calculated the time from LT to the date of
death. The cumulative incidence of death at 1 and 2 years is
reported with its corresponding 95% confidence interval
(95% CI). The STATA software (StataCorp, version 14.2)
was used for data analysis.
RESULTS
Liver Transplant Centers
A total of 200 patients were enrolled in the study. The total
number of transplanted patients per center was as follows:
Hospital Italiano from Buenos Aires: 64 (32%), Hospital
Universitario Fundación Favaloro: 36 (18%), Sanatorio
Allende: 33 (17%), Hospital Univeritario Austral: 32
(16%), Hospital Alemán 25 (12%), and Hospital Dr. Cosme
Argerich 10 (5%).
Indications for Liver Transplant
Primary diagnoses at time of listing are shown in Table 1.
Overall, 173 (86%) patients had cirrhosis, of which hepatitis
C and alcohol-related liver disease were the 2 most frequent
etiologies. Acute liver failure and other indications for LT
were registered in 10 (5%) and 17 (9%) patients,
Table 1. Characteristics of Patients on the Liver Transplant
Waiting List
Characteristics
Results
n ¼ 200
Age at transplant (y), median and IQR 50 (26e64)
Sex (male), no. (%) 116 (58%)
HIV positve, no. (%) 10 (5%)
Primary diagnosis at listing, no. (%)
Cirrhosis 173 (86%)
Hepatitis C 56 (32%)
Alcoholic liver disease 41 (24%)
Cryptogenic cirrhosis 27 (16%)
Autoimmune hepatitis 22 (13%)
Primary biliary cirrhosis 11 (6%)
Primary sclerosing cholangitis 6 (3%)
Nonalcoholic steatohepatitis 5 (3%)
Secondary biliary cirrhosis 3 (2%)
Hepatitis B 2 (1%)
Acute liver failure 10 (5%)
Autoimmune hepatitis 3 (30%)
Toxic hepatitis 2 (20%)
Hepatitis B 2 (20%)
Indeterminate 1 (10%)
Hepatitis A 1 (10%)
Other 1 (10%)
Other 17 (9%)
Hepatocellular carcinoma, no. (%) 35 (17%)
ABO blood group, no. (%)
O 88 (44%)
A 86 (43%)
B 23 (11%)
AB 3 (2%)
Diabetes, no. (%) 36 (18%)
MELD score at listing, median and IQR* 17 (14e23)
MELD score at transplant, median and IQR 25 (19e30)
Body weight, median and IQR 75 (64e84)
Child-Pugh score, median and IQR 10 (9e12)
Total bilirubin(mg/dL), median and IQR 5.5 (2.3e12.4)
Prothrombin time (seg), median and IQR 40 (26e75)
International normalized ratio prothrombin time,
median and IQR
1.9 (1.4e2.7)
Creatinine (mg/dL), median and IQR 1 (0.7e1.5)
Glomerular filtration rate at transplant, median
and IQR
88 (62e133)
Abbreviations: IQR, interquartile range; MELD, Model for End-Stage Liver
Disease.
*Excludes urgent category and MELD exception.
Table 2. Median (and Interquartile Range) Time on Waiting List
According to the ABO Group for Elective Patients (Patients
Listed as Urgent Are Excluded), N [ 190
Blood Type Number of Patients Days on the Waiting List
All 190 101 (27e295)
O 82 109 (31e386)
A 82 87 (20e266)
B 23 111 (13e207)
AB 3 47 (29e801)
Table 3. Median (and Interquartile Range) Time on the Waiting
List for Patients With Hepatocellular Carcinoma and
480 HADDAD, MARCIANO, CLERES ET ALrespectively. Thirty-five (17%) of the patients were trans-
planted with HCC, 19 (54%) of whom had a diagnosis of
hepatitis Cerelated cirrhosis. Of the 200 LTs performed in
this period, 190 were elective and 10 were emergency
candidates.Supplementary Points Subdivided According to ABO Group,
N [ 35
Blood Type Number of Patients Days on the Waiting List
All 35 117 (35e195)
O 14 164 (35e201)
A 17 76 (36e118)
B 4 162 (61e2230)Pretransplant Patient Characteristics and Time on Waiting
List
Baseline characteristics of the study population are shown in
Table 1. Most of the patients were middle-aged men, with a
median age of 50 (IQR 26 to 64) years. Sixty-seven (33%)
patients were between the ages of 60 and 70 years, and only7 (4%) patients were more than 70 years old at the time of
LT.
The median waiting time for the 190 elective patients was
101 (IQR 27 to 295) days. The median waiting time for the
10 emergency patients was 3 (IQR 2 to 4) days. Tables 2 and
3 show the median time on the waiting list according to the
ABO group for patients with and without MELD exception
for HCC, respectively.
Donor Characteristics
The median age of donors was 40 (IQR 27 to 53) years.
Seventy (35%) donors were older than 50 years. The oldest
donor was 84 years old. The most common causes of death
were cerebrovascular disorders and head trauma, in 98
(49%) and 86 (43%) cases, respectively. In regard to donor
history of infections, Chagas-positive, anti-hepatitis B core,
and hepatitis C virusepositive donors were reported in 11
(5%), 9 (4%), and 2 (1%) patients, respectively.
Immunosuppression
All patients received steroid-based induction regimens.
Sixty-eight (34%) patients received induction therapy with
an interleukin-2 receptor antagonist. The initial mainte-
nance regimen during the first 72 hours after LT included
steroids in all patients, calcineurin inhibitors in 100 (50%)
patients, and mycophenolate in 36 (18%) patients. Of the
100 patients who received calcineurin inhibitors, 76 (76%)
received tacrolimus, and 24 (24%) received cyclosporine.
None of the patients received mammalian target of rapa-
mycin (mTOR) inhibitors during the first 72 hours after LT.
Of the 153 patients who completed the 2-year follow up,
62 (40%) were receiving steroids, 133 (87%) calcineurin
inhibitors (79% tacrolimus, 21% cyclosporine), and 86
(56%) mycophenolate. A total of 23 (15%) patients were
receiving mTOR inhibitors, of whom 16 (70%) received
020
40
60
80
100
0 6 12 24
Calcineurin inhibitors
Tacrolimus and cyclosporine
Tacrolimus
Cyclosporine
0
20
40
60
80
100
0 6 12 24
Steroids
Steroids
Pe
rc
en
to
fp
a
en
ts
Months post-transplant
Fig 1. Proportion of patients
receiving steroids and calcineurine
inhibitors since transplant during
the study period. 0 ¼ Liver trans-
plant day, n ¼ 200; at 6 months,
n ¼ 184; at 12 months, n ¼ 179;
at 24 months, n ¼ 153.
LIVER TRANSPLANTATION IN ARGENTINA 481sirolimus and 7 (30%) received everolimus (Figs 1 and 2).
The main reasons for prescription of mTOR inhibitors
(either with or without CNI inhibitors) were renal failure in
13 (57%) patients, preoperative HCC in 4 (17%) patients
(CNI), neurotoxicity in 3 (14%) patients, HCC recurrence
in 2 (9%) patients, and refractory acute rejection in 1 (3%)
patient.Patient Outcomes and Posttransplant Complications
Of the 200 patients, 153 were alive after 2 years, 12 were
retransplanted, 28 died, and 7 were lost to follow up. The
overall survival rates of patients who survive past the first 48
hours after LT were 91% (95% CI 86% to 94%) and 85%
(95%CI 79 to 89%) at 1 and 2 years, respectively. The0
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tscauses of death are shown in Table 4. Of the 12 (6%)
patients who underwent retransplantation, the median time
between the primary transplantation and retransplantation
was 110 (IQR 11 to 361) days. The main indication of
retransplantation was hepatic artery thrombosis in 4 (34%)
patients, followed by chronic rejection in 3 (25%) patients,
biliary complications in 3 (25%) patients, primary non-
function in 1 (8%) patient, and hepatitis C virus recurrence
in 1 (8%) patient.Other Complications
During the first 6 months of LT, 54 (27%) patients experi-
enced 62 episodes of acute rejection. The severity of the
acute rejection episodes was as follows: 15 (24%) mild, 226 12 24
1 inhibitors
r sirolimus Everolimus
Fig 2. Proportion of patients
receiving mycophenolate and
mammalian target of rapamycin
(mTOR) inhibitors since transplant
during the study period. 0 ¼ Liver
transplant day, n ¼ 200; at 6
months, n ¼ 184; at 12 months,
n ¼ 179; at 24 months, n ¼ 153.
Table 4. Causes of Death After Liver Transplant
Cause of Death
Patients
N ¼ 28
Gastrointestinal bleeding 1 (4%)
Primary nonfunction 2 (7%)
Infection 14 (50%)
Bacterial infection 12 (43%)
Fungal infection 1 (4%)
Other 1 (4%)
Recurrence of hepatocellular carcinoma 1 (4%)
Recurrence of hepatitis C virus 2 (7%)
De novo tumor* 2 (7%)
Chronic rejection 1 (4%)
Others causes 5 (17%)
Cardiovascular 2 (7%)
Cerebrovascular 3 (11%)
*One lung and one colorectal cancer.
Table 5. Posttransplant Vascular and Biliary Complications
Complication
Total
N ¼ 200
Vascular complication* 19 (9%)
Thromboses of the hepatic artery 12 (63%)
Early 6 (50%)
Late 6 (50%)
Thromboses of the portal vein 7 (37%)
Early 3 (40%)
Late 4 (60%)
Biliary complication 39 (19%)
Biliary anastomotic stricture 26 (67%)
Ischemic-type biliary lesion 7 (18%)
Bile leak 6 (15%)
*Vascular complications were classified as early (occurring during the first 30
days after liver transplant) or late (occurring more than 30 days after liver
transplant).
482 HADDAD, MARCIANO, CLERES ET AL(35%) moderate, 16 (26%) severe; no data were available
for 9 (15%) of the episodes. A total of 194 infections in 130
(65%) patients were documented during the study period.
There were 117 (60%) bacterial infections, of which 49
(42%) occurred during the first month. Viral infections were
registered in 55 (28%) patients; cytomegalovirus (CMV)
infections were reported in 36 (65%) of them. Fungal in-
fections were documented in 15 (8%) patients; 14 (93%) of
them reported as Candida species and 1 case as cryptococcal
disseminated infection. Chagas transmission was docu-
mented in 3 (27%) of the 11 patients who received organs
from Trypanosoma cruzieinfected donors. All were treated
with benznidazole.
Of the 153 patients who were alive 2 years after LT, 87
(57%) were diabetic (55 [63%] of them with diagnosis of
NODM). Seventy-seven (50%) patients were dyslipidemic.
The median creatinine at 2 years of LT was 1.18 mg/dL
(IQR 0.9 to 1.4), and median GFR was 61.5 (IQR 48 to 80)
mL/min. Forty (26%) patients had a GFR lower than 50
mL/min; only 3 of them were under everolimus, and 7 under
sirolimus. Of the 35 patients transplanted with HCC, 7
(20%) developed HCC recurrence within 2 years of LT.
Vascular and biliary complications and readmission are
shown in Table 5 and Fig 3, respectively.DISCUSSION
Seventeen percent of LTs are currently being performed in
Latin America, and the top LT rates were found in
Argentina, with 10.4 LT per million people per year [1].
Despite the comparable outcomes to those in Europe and
North America [9], there is still a lack of data from our
region.
As expected, cirrhosis continues to represent the main
indication of LT, with a large predominance of hepatitis
Cerelated cirrhosis within this group of patients. It is
noteworthy that autoimmune cirrhosis continues to be a
leading cause of LT in Argentina [18,19]. We found that
autoimmune hepatitis (AIH) was the main etiology inurgent LT, in contrast to the situation in Europe and North
America, where AIH is considered a relatively rare disease
and represents an infrequent indication for LT, accounting
for only 4% to 5% of LT procedures [20,21].
In the pre-MELD era, patients with blood group O had
longer waiting times for LT than patients with other blood
groups [22,23]. Although our study was not powered to
analyze this issue, a clinically significant shorter waiting time
for LT was observed for patients with blood type A than for
patients with other blood types.
We found that 35% of our donors were past the age of 50
years; this is also similar to reports from the United States
[24]. Contradictory results have been obtained from
different studies, according to which the donor age is an
independent risk factor on the LT outcomes [25e28]. In our
region, the use of older donors is crucial because of donor
shortage.
In our study, we found that almost 40% of the patients
were readmitted during the first 6 months of LT; infectious
complications were frequent, affecting 65% of the patients,
and were caused predominantly by bacterial origin. This is
similar to what has been previously reported [29,30].
In our region, extended screening for endemic infections
is mandatory. It is known that the transmission rate from
Trypanosoma cruzi seropositive donors to seronegative LT
recipients is approximately 20% [31]. In our study, we found
that 5% of the donors were positive for Trypanosoma cruzi,
and had similar transmission rates to seronegative
recipients.
Some regional public health problems, such as Chagas
disease, tuberculosis, and some regional parasitoses, deserve
special consideration during the pretransplantation assess-
ment to implement adequate treatment or posttransplant
prophylaxis. Biliary tract complications occurred in 19% of
the patients, which is consistent with worldwide reports
[32e34]. Anastomotic biliary strictures followed by ischemic
lesions were the most frequent complications. Vascular
complications occurred in 9% of the patients and mostly
consisted of hepatic artery thrombosis, which was observed
Fig 3. Cumulative incidence of
readmission to the hospital at 3
months (n ¼ 43/186), 6 months
(n ¼ 71/184), and 12 months
(n ¼ 96/179) after liver transplant.
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[35]. Acute cellular rejection episodes were observed in
27% of the patients, which is lower than previously reported
[36], and could be explained by the fact that protocol bi-
opsies were not performed in all centers.
Regarding long-term complications, it was striking to find
that 57% of the patients had diabetes and most of them had
NODM at 2 years after LT. Immunosuppressive drugs, and
moreover steroids, have a known diabetogenic effect and
are a major contributor to the development of NODM. It is
important to manage NODM with therapeutic and pre-
ventive steps such as individual use of the immunosup-
pressive regimen with corticosteroid tapering or
discontinuation, as early as possible. We found that 2 years
after LT, 40% of recipients were still receiving steroids, a
situation that must be reversed because of the knowledge
gained from already-published data showing a negative
impact of NODM on patient and graft survival after LT
[14,37].
It is known that mortality is higher in LT recipients with
posttransplant renal failure than in patients with preserved
renal function [6,38,39]. Two years after LT, 1 in every 4
patients in our study had a GFR lower than 50 mL/min. This
situation underestimates the real burden of post-LT renal
failure because patients who died or were retransplanted
before that time were not taken into account. Although
current guidelines suggest that CNI reduction or CNI-free
protocols might overcome this issue [40,41] in our study, 2
years after LT, only 10 (25%) patients with GFR lower than
50 mL/min were previously switched to mTOR inhibitors, or
used a combination of low-dose CNI and mTOR inhibitors.
Finally, we found LT survival rates of 91% and 85% at 1
and 2 years, respectively. It should be noted that patients
who died during the first 2 days of LT were excluded from
this analysis. This is a limitation of our study, which was
mainly designed to study post-LT long-term outcomes. Inconclusion, we believe that the information contained in this
article might be of value to review current practices and
develop local policies.REFERENCES
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